Skip to main content
Clinical Trials/JPRN-UMIN000042360
JPRN-UMIN000042360
Completed
Phase 2

Prospective Study Evaluating Efficacy and Safety of Olanzapine and Aprepitant for Cisplatin-induced Nausea and Vomiting in Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma - PROACT study

Department of Gastroenterology and Hepatology, Kurashiki Central Hospital0 sites50 target enrollmentNovember 5, 2020

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Hepatocellular carcinoma
Sponsor
Department of Gastroenterology and Hepatology, Kurashiki Central Hospital
Enrollment
50
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 5, 2020
End Date
March 31, 2023
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Department of Gastroenterology and Hepatology, Kurashiki Central Hospital

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) pregnant, possibly pregnant or breastfeeding 2\) regular use of olanzapine or other antipsychotic drugs 3\) previous participation in this study 4\) moderate or severe (NRS 4 or more) nausea 5\) considered not appropriate for participating in this study

Outcomes

Primary Outcomes

Not specified

Similar Trials